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Christina M. Beck,a* Basil R. Perkins,a* David A. Low,a,b Christopher S. Hayesa,b
Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa
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ABSTRACT Contact-dependent growth inhibition (CDI) systems encode CdiA effec-
tors, which bind to specific receptors on neighboring bacteria and deliver C-terminal
toxin domains to suppress target cell growth. Two classes of CdiA effectors that
bind distinct cell surface receptors have been identified, but the molecular basis of
receptor specificity is not understood. Alignment of BamA-specific CdiAEC93 from
Escherichia coli EC93 and OmpC-specific CdiAEC536 from E. coli 536 suggests that the
receptor-binding domain resides within a central region that varies between the two
effectors. In support of this hypothesis, we find that CdiAEC93 fragments containing
residues Arg1358 to Phe1646 bind specifically to purified BamA. Moreover, chimeric
CdiAEC93 that carries the corresponding sequence from CdiAEC536 is endowed with
OmpC-binding activity, demonstrating that this region dictates receptor specificity. A
survey of E. coli CdiA proteins reveals two additional effector classes, which presum-
ably recognize distinct receptors. Using a genetic approach, we identify the outer
membrane nucleoside transporter Tsx as the receptor for a third class of CdiA effec-
tors. Thus, CDI systems exploit multiple outer membrane proteins to identify and en-
gage target cells. These results underscore the modularity of CdiA proteins and sug-
gest that novel effectors can be constructed through genetic recombination to
interchange different receptor-binding domains and toxic payloads.
IMPORTANCE CdiB/CdiA two-partner secretion proteins mediate interbacterial com-
petition through the delivery of polymorphic toxin domains. This process, known as
contact-dependent growth inhibition (CDI), requires stable interactions between the
CdiA effector protein and specific receptors on the surface of target bacteria. Here,
we localize the receptor-binding domain to the central region of E. coli CdiA.
Receptor-binding domains vary between CdiA proteins, and E. coli strains collectively
encode at least four distinct effector classes. Further, we show that receptor specific-
ity can be altered by exchanging receptor-binding regions, demonstrating the mod-
ularity of this domain. We propose that novel CdiA effectors are naturally generated
through genetic recombination to interchange different receptor-binding domains
and toxin payloads.
KEYWORDS bacterial competition, cell-cell adhesion, self/nonself discrimination,
toxin immunity proteins, type V secretion system
Bacteria have long been known to compete with one another using diffusibleantibiotics and bacteriocins (1, 2). More recently, type IV, V, and VI secretion
systems have been found to mediate interbacterial competition in a proximity-
dependent manner (3–6). This phenomenon was first described for Escherichia coli
isolate EC93, which uses a type Vb secretion system to bind and inhibit the growth of
other E. coli cells (3). Because this inhibition requires direct cell-to-cell contact, the
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mechanism has been termed contact-dependent growth inhibition (CDI). Related CDI
systems have since been identified and characterized in other Gram-negative bacteria,
where they play important roles in interstrain competition and self/nonself discrimina-
tion (7–11). CDI is mediated by the CdiB/CdiA family of two-partner secretion proteins.
CdiB is an Omp85 transport protein that exports and presents toxic CdiA proteins on
the cell surface. CdiA effectors range from 180 to 630 kDa depending on bacterial
species (12), but each is predicted to form an elongated filament projecting from the
inhibitor cell. Upon binding a specific receptor, CdiA transfers its C-terminal toxin
domain (CdiA-CT) into the target bacterium through an incompletely understood
translocation pathway (13, 14). CdiA-CT sequences vary considerably between effector
proteins, but most toxins either degrade nucleic acids or form pores in target cell
membranes (9, 15–19). To prevent self-intoxication, CDI bacteria produce CdiI immu-
nity proteins, which bind the CdiA-CT domain and neutralize its activity. Because CdiA-CT
sequences are highly variable and the domains have distinct three-dimensional structures
(16, 20–23), immunity proteins protect against only cognate toxins deployed by sibling
cells. Thus, CDI confers a selective advantage against nonisogenic competitors, and toxin
immunity polymorphism provides a mechanism for self/nonself discrimination.
CdiA-receptor-binding interactions also play a critical role in self/nonself recogni-
tion. Using a genetic approach, Aoki et al. identified BamA as the receptor for the
CdiAEC93 effector from E. coli EC93 (24). BamA is an essential outer membrane -barrel
protein found in all Gram-negative bacteria (25). Though BamA proteins share a high
degree of sequence identity between enterobacteria, the surface-exposed extracellular
loops vary dramatically between species (26, 27). Thus, CdiAEC93 effectively targets
E. coli strains but does not recognize closely related bacteria like Enterobacter cloacae,
even though BamA from E. cloacae (BamAECL) and BamA from E. coli (BamAEco) share
~95% sequence identity (28). Variations in bacterial surface antigens are thought to
reflect the selective pressures exerted by bacteriophages and adaptive immune sys-
tems (29, 30). Because surface epitopes vary dramatically between bacteria, the CdiA
effector family must collectively recognize many distinct receptors. Accordingly, we
recently found that CdiAEC536 from uropathogenic E. coli 536 uses heterotrimeric
OmpC-OmpF as a receptor (31). The E. coli pan-genome encodes at least 220 distinct
OmpC porins, with much of the sequence variability localized to extracellular loops L4
and L5 (31–33). These loops appear to be recognition epitopes for CdiAEC536, and
consequently, several E. coli OmpC variants are not recognized by this effector. Notably,
CdiAEC536 binds OmpC and OmpF from E. cloacae ATCC 13047 (31), suggesting that
E. coli 536 could use CDI to inhibit other species. Thus, CDI-target cell interactions are
complex and idiosyncratic. However, one common and perhaps universal feature is the
recognition of “self” receptors, which promotes the autoaggregation of CDI sibling
cells (3, 34). CDI-dependent cell-cell adhesion also contributes significantly to biofilm
formation (10, 35–38), and recent work suggests that CDI-mediated toxin exchange is
exploited for intercellular communication between siblings (39). These findings indicate
that CDI plays an important role in bacterial cooperation, and its toxin delivery activity
excludes nonisogenic cells from group activities.
Though CDI recognition epitopes have been localized on BamA and OmpC (28, 31),
the corresponding receptor-binding domains in CdiA have not yet been identified. In
this report, we use a combination of biochemical and molecular genetic approaches to
map the receptor-binding region within E. coli CdiA effectors. Previous work with
truncated CdiAEC93 indicates that its BamAEco-binding domain resides within the
N-terminal 2,000 residues (38). We find that CdiAEC93 fragments containing residues
Arg1358 to Phe1646 interact stably with BamAEco but not with the closely related
BamAECL protein. These CdiAEC93 residues comprise an unannotated central segment
located between the FHA-1 and FHA-2 peptide repeat regions. Notably, E. coli CdiA
proteins can be divided into four major classes based on sequence variation in the
putative receptor-binding region. Using chimeric effectors, we show that CdiAEC93 is
redirected to bind OmpC when residues Ser1347 to Tyr1636 are replaced with the
corresponding region from CdiAEC536. Given the variability between effector classes, we
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reasoned that a third class of CdiAs likely recognizes an uncharacterized receptor. Using
the CDISTECO31 system from E. coli STEC_O31 as a model, we identify the outer
membrane nucleoside transporter Tsx as the receptor for class III effectors. Thus, CdiA
proteins collectively recognize diverse receptors, and their receptor-binding domains
are interchangeable between effectors. This modularity suggests that receptor-binding
and toxin domains are actively recombined to generate novel effectors.
RESULTS
Localization of the BamA-binding region in CdiAEC93. We previously reported
that truncated CdiAEC93 lacking residues Ala1931 to Lys3242 is exported to the cell
surface and retains BamAEco-binding activity (38). Further truncation abrogates adhesin
function, but these smaller proteins are not exported efficiently and appear to be
degraded rapidly. Therefore, we took a biochemical approach to define the receptor-
binding region more precisely. We generated a series of His6-tagged CdiAEC93 frag-
ments (Fig. 1A) and tested them for binding interactions with purified BamA. Using
Ni2 affinity chromatography, we found that BamAEco copurifies with CdiAEC93 frag-
ments containing residues Arg1358 to Phe1646 and Arg1358 to Arg2123 (Fig. 1B). In
contrast, CdiAEC93 fragments containing the FHA-2 repeat region and the pretoxin-
VENN domain did not interact stably with BamAEco (Fig. 1A and B). To ascertain binding
specificity, we also tested for stable interactions with BamAECL from E. cloacae. Though
the two BamA proteins share 94.8% sequence identity, BamAECL did not copurify with
any of the His6-tagged CdiAEC93 fragments (Fig. 1B). Thus, the in vitro binding specificity
conforms to prior work showing that BamAECL is not recognized as a receptor by
CdiAEC93 (28). These data strongly suggest that the BamAEco-binding domain resides
between residues Arg1358 and Phe1646 of CdiAEC93.
FIG 1 Localization of the BamAEco-binding region within CdiAEC93. (A) CdiAEC93 domain architecture. Domains and
peptide repeat regions are depicted according to InterPro. TPS indicates the two-partner secretion transport
domain, and also shown are FHA-1 (PF05594), FHA-2 (PF13332), the pretoxin-VENN domain (PF04829), and the
CdiA-CT region. His6 epitope-tagged CdiAEC93 fragments used for BamA interaction experiments are depicted. (B)
Affinity copurification of BamA with His6-tagged CdiAEC93 fragments. Refolded BamAEco or BamAECL was incubated
with His6-tagged CdiAEC93 and then subjected to Ni2-affinity chromatography. The input fraction and final elution
samples were analyzed by immunoblotting using polyclonal antisera to BamAEco.
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CdiA receptor-binding domains are modular. The putative receptor-binding re-
gion of CdiAEC93 (from Ser1379 to Tyr1636) shares only ~24% sequence identity with
the corresponding region of CdiAEC536 (Gln1377 to Trp1668) from uropathogenic E. coli
536 (Fig. 2; see also Fig. S1 in the supplemental material). Therefore, we reasoned that
sequence divergence over this region could determine receptor specificity. To test this
hypothesis, we replaced residues Ser1347 to Tyr1636 of CdiAEC93 with Ala1345 to
Trp1668 from CdiAEC536 (Fig. 2) and determined the receptor-binding specificity of the
resulting chimera using a flow cytometry-based cell-cell adhesion assay (40). In this
assay, CdiA-expressing inhibitor cells are labeled with green fluorescent protein (GFP)
and mixed at a 5:1 ratio with DsRed-labeled target bacteria. After the populations are
allowed to interact, the cell suspension is analyzed by flow cytometry for events that
exhibit both GFP and DsRed fluorescence (Fig. 3A), which are quantified as inhibitor-
target cell aggregates. Control experiments show that 5% of target bacteria adhere
nonspecifically to mock (CDI) inhibitor cells (Fig. 3A and B). In contrast, cells that
express CdiA bind to target bacteria in a receptor-dependent manner. CdiAEC93-
expressing cells bound ~80% of bamAEco-target bacteria but failed to aggregate with
bamAECL targets (Fig. 3A and C). Similarly, inhibitor cells that express CdiAEC536 bind a
substantial fraction of ompCEC536 target bacteria but exhibited only background adhe-
sion with ΔompC targets (Fig. 3A and D). As predicted, chimeric CdiAEC93 containing the
putative receptor-binding region from CdiAEC536 recognized target cells in an ompC-
dependent manner (Fig. 3A and E). Moreover, because this chimera was expressed at
approximately the same level as CdiAEC536 (Fig. S2), the grafted domain appears to bind
OmpF-OmpC with the same avidity as in its native context. These data, together with
the in vitro binding results, indicate that the central regions of CdiAEC93 and CdiAEC536
are responsible for receptor recognition.
The CVR is required for OmpC-dependent toxin delivery. Though the receptor-
binding region chimera supported robust OmpC-dependent adhesion, this effector
protein did not inhibit target cell growth in competition cocultures (Fig. 4D). In contrast,
inhibitors expressing CdiAEC93 outcompeted target cells approximately 105-fold in
cocultures (Fig. 4B), and cells that deploy CdiAEC536 exhibited a greater than 100-fold
advantage (Fig. 4C). In each instance, CDI inhibitors only outcompeted target cells
that express the appropriate CdiA receptor (Fig. 4B and C). Together, these results
suggest that the chimera is defective for toxin delivery. We noted that the CdiAEC93
region spanning Ala1910 to Gly2205 also diverges significantly with CdiAEC536 and that
CdiAEC536 contains a 69-residue insertion in this region (Fig. 2 and Fig. S1). Because this
region is conserved between CdiAEC536 homologues that bind OmpC-OmpF, we refer
to this sequence as the “covarying region” (CVR). We explored the function of this
FIG 2 CdiAEC93-CdiAEC536 chimeras. CdiAEC93 and CdiAEC536 sequences are shown schematically. Shared residues
are indicated in white, and effector-specific residues are indicated in blue and yellow. The residues demarcating the
receptor-binding region (RBR) and covarying region (CVR) are indicated, as is the VENN motif that defines the
CdiA-CT toxin region.
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FIG 3 Cell-cell adhesion. (A) Flow cytometric analysis of CDI-dependent cell-cell adhesion. GFP-labeled
inhibitor cells were mixed at a 5:1 ratio with DsRed-labeled target bacteria, and the cell suspension was
(Continued on next page)
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sequence by replacing CdiAEC93 residues Ser1347 to Gly2205 with the receptor-binding
and covarying regions of CdiAEC536 (Ala1345 to Gly2310) (Fig. 2). The resulting chimera
was expressed stably (Fig. S2) and supported ompC-dependent cell-cell adhesion
comparably to wild-type CdiAEC536 (Fig. 3A and G). Moreover, CdiAEC93 carrying the
FIG 3 Legend (Continued)
analyzed by flow cytometry for dual green/red fluorescent events. CdiA protein identity is indicated
schematically in the left margin, and target cell genetic backgrounds are indicated along the top. (B to G)
CdiA-dependent cell-cell adhesion was quantified for each effector protein: mock CDI (B), CdiAEC93 (C),
CdiAEC536 (D), CdiAEC93 with the receptor-binding region (RBR) from CdiAEC536 (E), CdiAEC93 with the
covarying region (CVR) from CdiAEC536 (F), and CdiAEC93 with both RBR and CVR from CdiAEC536 (G). The
fraction of target bacteria bound to inhibitor cells was quantified for two independent experiments. Data
are presented as averages  standard errors. UPEC, uropathogenic E. coli.
FIG 4 Competition cocultures. Target bacteria with the indicated bamA and ompC alleles were cocultured with inhibitor strains that express the following CdiA
effectors: mock CDI– (A), CdiAEC93 (B), CdiAEC536 (C), CdiAEC93 with the receptor-binding region (RBR) from CdiAEC536 (D), CdiAEC93 with the covarying region (CVR)
from CdiAEC536 (E), and CdiAEC93 with both RBR and CVR from CdiAEC536 (F). Viable inhibitor and target cells were enumerated as CFU milliliter1, and the
competitive index was calculated as final inhibitor-to-target cell ratio divided by the initial ratio for each coculture. Competitive indices are reported as
averages  standard errors for two independent experiments. UPEC, uropathogenic E. coli.
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heterologous receptor-binding and covarying regions also inhibited target bacteria in
an ompC-dependent manner (Fig. 4F). In contrast, another CdiAEC93 chimera containing
only the covarying region from CdiAEC536 (Pro1669 to Gly2310) retained BamA-binding
specificity (Fig. 3A and F) and inhibited target cells in a bamAEco-dependent manner
(Fig. 4E). Collectively, these data suggest that CdiAEC536 residues Pro1669 to Gly2310
may be important for toxin delivery through the OmpC-OmpF receptor pathway.
Identification of the receptor for CdiASTECO31. We surveyed all identifiable E. coli
CdiA effectors in the NCBI protein database and found that they segregate into at least
four classes based on receptor-binding region sequences. CdiAEC93 defines the BamA-
binding class I effectors, and CdiAEC536 is the paragon for class II effectors that
recognize OmpC-OmpF. Class III CdiA proteins are closely related to class I and II over
the two-partner secretion (TPS) transport domain and filamentous hemagglutinin
(FHA)-peptide repeat regions but diverge significantly at the receptor-binding region
(Fig. 5; see also Fig. S1). Class IV CdiA proteins appear to be more distantly related and
share little sequence identity with the other three classes over the FHA-1 peptide repeat
region (Fig. S3). To determine whether class III CdiA recognizes a unique receptor, we
cloned the cdiBAI gene cluster from E. coli STEC_O31 and tested its activity in growth
competitions. Class III CdiASTECO31 (NCBI reference sequence WP_001385946.1) carries a
C-terminal EndoU RNase toxin domain, and cells deploying this effector outcompeted
target bacteria after 4 hours of coculture (Fig. 6A). Having established growth inhibition
activity, we used a genetic approach to identify the receptor for CdiASTECO31. We
subjected target cells to mariner transposon mutagenesis and selected for CDISTECO31-
resistant (CDIr) mutants. We isolated 12 CDIr clones from three independently prepared
mutant pools and identified transposon insertion sites. Four of the CDIr mutants carried
independent insertions in the ptsG gene, which encodes the fused IIB and IIC compo-
nents of the glucose phosphotransferase system (PTS). We previously reported that
ptsG null alleles also confer resistance to CDI toxins from E. coli 3006 and NC101 (14).
CdiA-CTSTECO31, CdiA-CT3006, and CdiA-CTNC101 all share the same “translocation” do-
main, which is thought to bind PtsG and mediate toxin transport from the periplasm
into the target cell cytosol (14). The remaining eight CDIr mutants were disrupted in tsx
(Fig. 6A), which encodes an outer membrane nucleoside transporter. To confirm the
role of Tsx in CDISTECO31, we tested target cells carrying a nonpolar Δtsx mutation and
found that they were resistant to growth inhibition (Fig. 6A). Moreover, complemen-
tation of Δtsx target cells with plasmid-borne tsx restored sensitivity to growth inhibi-
tion (Fig. 6A). Finally, we used flow cytometry to demonstrate that Tsx is required for
cell-cell adhesion between target bacteria and CdiASTECO31-expressing inhibitor cells
(Fig. 6B). Together, these results show that the distinct receptor-binding region of class
III CdiASTECO31 recognizes Tsx.
FIG 5 Comparison of class I, II, and III CdiA effectors. The CdiAEC93, CdiAEC536, and CdiASTECO31 proteins are
presented schematically. Residues shared by all three proteins are shown in white, and residues shared by two
CdiAs are shown in gray. Effector-specific residues are shown in blue (CdiAEC93), green (CdiAEC536), and orange
(CdiASTECO31).
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DISCUSSION
The results presented here show that CdiA effectors from E. coli strains bind target
bacteria using at least three cell surface receptors. Receptor specificity for the different
CdiA classes is determined by an unannotated stretch of ~300 residues located
between the FHA-1 and FHA-2 peptide repeat regions (see Tables S1, S2, S3, and S4 in
the supplemental material). CdiAEC93 is the paragon for class I effectors, which bind
specifically to BamA from E. coli (28). Class II effectors recognize heterotrimeric OmpC-
OmpF osmoporins (31), and here, we show that class III effectors bind the outer
membrane nucleoside transporter Tsx. The receptor-binding regions of class I, II, and III
effectors share 24 to 27% pairwise sequence identity, and each domain contains a
conserved central FHA-1 element (Fig. S1). These observations suggest that the classes
diverged from a common ancestral sequence and that the three receptor-binding
domains adopt similar conformations. The domains also exhibit some mutational drift
within each class, though it is not clear whether these minor sequence variations
influence receptor specificity. Class I effectors carry nine different receptor-binding
FIG 6 CdiASTECO31 uses Tsx as a receptor to bind target bacteria. (A) E. coli Δtsx mutants are resistant to
CdiASTECO31-mediated growth inhibition. Eight independent transposon insertions within tsx were iden-
tified in selections for CDI-resistant mutants. Inhibitor cells (CDISTECO31 or CDI mock) were cocultured
with tsx or tsx target bacteria in shaking broth for 4 hours as described in Materials and Methods.
Viable inhibitor and target cells were enumerated as CFU, and the competitive index was calculated as
the final inhibitor-to-target cell ratio divided by the initial ratio. Competitive indices are presented as
averages  standard errors. (B) Tsx is required for CdiASTECO31-dependent cell-cell adhesion. The fraction
of red fluorescent target bacteria bound to green fluorescent inhibitor cells was quantified for two
independent experiments. Data are presented as averages  standard errors.
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sequences that arise from combinations of 17 missense changes (Table S1). Class II
receptor-binding regions are less polymorphic with only nine missense variations
(Table S2), and there are 14 distinct class III receptor-binding sequences (Table S3). Class
IV E. coli CdiA effectors have diverged from the other three classes but still share the
same overall domain structure (Fig. S3). Given the similarities in effector architecture,
we predict that the receptor-binding domain of class IV effectors also resides between
the FHA-1 and FHA-2 regions. Notably, class IV cdi gene clusters also encode a
predicted HlyC-type lysyl acyltransferase (14). The functional significance of this acyl-
transferase has not yet been explored, but it presumably modifies CdiA and/or CdiB to
promote cell adhesion and growth inhibition activities. Additionally, the database
contains three CdiA proteins from E. coli isolates SWW33 (WP_001764992.1), upec-172
(WP_052432358.1), and 696_ECOL (WP_049080366.1) that do not fit into the four major
classes. These proteins are most closely related to class IV CdiA but have longer FHA-1
repeat regions and diverge over the central (putative) receptor-binding region (Fig. S4).
Moreover, the three effectors are encoded by cdi gene clusters that lack the charac-
teristic hlyC acyltransferase of class IV loci. These observations suggest that these three
CdiA proteins constitute a fifth effector class that probably recognizes yet another cell
surface receptor.
Sequence alignments of class I, II, and III CdiA effectors predict that their receptor-
binding domains are interchangeable. This hypothesis is supported by data showing
that chimeric CdiAEC93 carrying a class II receptor-binding region is endowed with
OmpC-binding activity. Though this chimera appears to bind OmpC-OmpF with the
same avidity as wild-type CdiAEC536, it does not inhibit target bacteria, indicating that
toxin delivery function is compromised. Growth inhibition activity is restored when the
covarying region is grafted together with the receptor-binding region. The latter result
suggests that the covarying region of CdiAEC536 is critical for toxin delivery through the
OmpC pathway. However, chimeric CdiAEC93 carrying the covarying region from Cdi-
AEC536 inhibits target bacteria in a BamAEco-dependent manner, showing that this
sequence is not solely dedicated to the OmpC-OmpF pathway. In the context of
domain modularity, these observations raise the possibility that specific toxin families
may be excluded from certain receptor-mediated delivery pathways. Surveys of CdiA
proteins show that some toxin families tend to be paired with specific receptor-binding
domains. For example, Ntox28 RNase domains are found only on class II effectors in
E. coli (Table S2). However, Ntox28 toxins are very effective at killing target bacteria
when experimentally grafted onto class I CdiAEC93 (13, 14, 41). Thus, the apparent bias
in naturally occurring effectors does not necessarily reflect domain incompatibility. In
fact, we have shown that CdiAEC93 can deploy over a dozen heterologous toxin
domains (9, 13, 14, 19–21, 41, 42), even though many of the grafted CdiA-CT sequences
are not found on class I effectors. Moreover, the database shows significant combina-
torial flexibility for some toxin families. For example, endonuclease NS_2 toxin domains
are associated with each of the four major effector classes in E. coli (Tables S1 to S4).
Comprehensive analysis of E. coli CdiA proteins reveals that each effector class is
associated with multiple different toxin families (Tables S1 to S4). Taken together, these
observations suggest that new CdiA effectors are assembled through genetic recom-
bination to exchange receptor-binding domains and toxic payloads.
The location of the receptor-binding region has implications for the structure and
presentation of CdiA on the inhibitor cell surface. CdiA effectors are thought to be
structurally similar to the FhaB adhesins of Bordetella species because the protein
families share related domain architectures (3, 12). FhaB is synthesized initially as a
370-kDa precursor, from which the C-terminal “prodomain” is removed to yield a
mature filamentous hemagglutinin (FHA) fragment of ~220 kDa (43, 44). FHA is
monomeric and extends about 50 nm in length (45). The central shaft of FHA corre-
sponds to the FHA-1 peptide repeat region, which is predicted to form a right-handed
-helix with a 4.8-Å pitch per 20-residue repeat (45, 46). According to this model, the
FHA-1 repeat region of CdiAEC93 should form a filament 30 to 35 nm in length. It is less
clear that the CdiA FHA-2 repeat region is homologous to the FhaB prodomain. Though
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the prodomain contains a short FHA-2 region (Phe2927 to Gly3086), CdiA and FhaB
share little sequence identity over this region. Moreover, FhaB lacks a C-terminal toxin
domain and does not mediate interbacterial competition (47). Nevertheless, FhaB and
CdiA are processed in a similar manner, with immunoblot analysis revealing a stable
N-terminal CdiA fragment of ~230 kDa (see Fig. S2). This processed fragment almost
certainly retains adhesin activity, because truncated CdiAEC93 lacking the FHA-2 and
CdiA-CT regions is still exported to the cell surface and mediates BamAEco-dependent
adhesion (38). These observations raise questions about the location of the FHA-2/
CdiA-CT regions relative to the cell surface. Current models assume that the CdiA C
terminus projects away from the inhibitor cell to facilitate toxin transfer to target
bacteria. However, we propose that the receptor-binding domain should be positioned
at the distal tip of the filament (Fig. 7), where it can easily interact with target bacteria.
Studies on FhaB biogenesis from the Cotter lab provide further support for the
topological model presented in Fig. 7 (48). Their work indicates that the C-terminal
prodomain is retained in the periplasm during FhaB export and processing. Thus, both
N and C termini of FhaB remain within an intracellular compartment while the FHA-1
region assembles into a -helix on the cell surface (48). It is not clear how the FhaB
chain is exported as a tethered loop; however, their work predicts that the CdiA
receptor-binding domain should be located at the distal tip of the FHA-1 repeat
filament. Further, the model suggests that the FHA-2/CdiA-CT region is sequestered
within the inhibitor cell periplasm prior to receptor recognition (Fig. 7). The latter
prediction is consistent with unpublished data from our laboratories showing that the
C-terminal region is protected from extracellular protease, whereas the N-terminal TPS
domain and FHA-1 region are rapidly degraded by this treatment. If this model is
correct, then receptor recognition must induce an extraordinary change in CdiA
conformation to transfer the CdiA-CT toxin domain from the inhibitor cell periplasm
into the target bacterium.
MATERIALS AND METHODS
Bacteria, growth conditions, and competition cocultures. Bacteria used in this study are listed in
Table 1. All strains were grown at 37°C in lysogeny broth (LB) or on LB agar unless otherwise indicated.
Media were supplemented with antibiotics at the indicated concentrations: ampicillin (Amp), 150 g
ml1; chloramphenicol (Cm), 33 g ml1; kanamycin (Kan), 50 g ml1; rifampin (Rif), 200 g ml1; and
tetracycline (Tet), 15 g ml1. The ΔompC::kan allele from the Keio collection (49) was amplified using
FIG 7 Topological model for CdiA. The constituent domains of cell surface CdiA are labeled and color
coded as in Fig. 1. CdiB is represented as a barrel in the outer membrane (OM). The proposed model is
based on unpublished protease protection data and the work of Noël et al. (48).
Ruhe et al. ®
March/April 2017 Volume 8 Issue 2 e00290-17 mbio.asm.org 10
oligonucleotides ompC(UPECswap)-Sac (5=-TTT GAG CTC CTG GAA ATT ATG CGG ATG) and
ompC(UPECswap)-Kpn (5=-TTT GGT ACC CCA CAG ATT CAC CAG C), and the product was recombined
into E. coli CH9597 cells carrying plasmid pSIM5 (50). The ompCEC536-kan allele (31) was introduced into
E. coli CH9597 in the same manner. Kan resistance cassettes were subsequently removed with FLP
recombinase. Plasmid exchange was used to displace pZS21amp-bamA with Kan-resistant pZS21-bamA
or pZS21-bamAECL (28). The Δtsx::kan gene disruption was transduced into E. coli EPI100 that expresses
recA from pCH9674, which was subsequently cured by growing the resulting strain at 42°C. For
competition cocultures, inhibitor and target bacteria were adjusted to an optical density at 600 nm
(OD600) of 0.05 and then mixed at a 10:1 ratio and incubated in shaking LB medium for 4 h at 37°C. Cell
suspensions were diluted into 1 M9 salts and plated onto antibiotic selective LB-agar to enumerate
inhibitor and target cells as CFU per milliliter. Competitive indices were calculated as the ratio of target
to inhibitor cells at 4 h divided by the ratio at the beginning of coculture.
Plasmid constructions. Plasmids used in this study are listed in Table 2. The bamAEco gene from
E. coli MG1655 was amplified with oligonucleotides bamA(Δss)-Spe (5=-TTT ACT AGT GAA GGG TTC GTA
GTG AAA G) and bamA-rev-Sal (5=-TCC TTT GTC GAC AAC ACT TAC CAG GTT TTA CC), digested with
SpeI/SalI, and ligated to SpeI/XhoI-digested plasmid pCH7277. The resulting pCH9216 construct over-
produces BamAEco under the control of the bacteriophage T7 promoter. The bamAECL gene from
Enterobacter cloacae ATCC 13047 was amplified with primer pair bamA(Δss)-Spe and Ecloa-bamA-Sal-rev
(5=-TTT GTC GAC GAG AAT TAC CAG GTT TTA CC) and cloned in the same manner. Fragments of cdiAEC93
were amplified from plasmid pDAL660Δ1-39 using the following primer pairs: EC93-cdiA(R1358)-Spe
(5=-TTT ACT AGT CGT TCC GGT AAT ATT GAA ACC) and EC93-cdiA(R2123)-Xho (5=-TTT CTC GAG TTA CCG
GGT GGT CTG ATG GC), EC93-cdiA(R1358)-Spe and EC93-cdiA(F1646)-Xho (5=-TTT CTC GAG CTA AAA ATA
ACC ATT GTT ACC GGA TGG), EC93-cdiA(G1953)-Spe (5=-TTT GAG CTC ACT AGT GGT GAC AGC GTG TTA
CTG G) and EC93-cdiA(N2556)-Xho (5=-TTT CTC GAG GAT CCT AAT TGC TTT TAA TTT TGT CCT GGC),
EC93-cdiA(N2556)-Spe (5=-TTT GAG CTC ACT AGT AAT TAC GAT TCT GTC CGG GAA C) and cdiA(V2727)-
Xho (5=-TTT CTC GAG GAT CCT AGA CGA TGT TAC TCA TCT GAC C), and EC93-cdiA(Q2681)-Spe (5=-TTA
ACT AGT CAG GAT ATT GCC GGG CTC) and EC93-cdiA(A2909)-Xho (5=-TTA CTC GAG TTA TGC ATT ATT
CTC AAC CGA G). The resulting PCR products were digested with SpeI/XhoI and ligated to plasmid
pCH7277 to generate constructs that overproduce His6-tagged CdiAEC93 fragments.
The cdiBAIEC536 gene cluster (ordered loci, ECP_4581, ECP_4580, and ECP_4579) was amplified from
E. coli 536 genomic DNA using oligonucleotides UPEC-cdiB-Not-for (5=-TTT GCG GCC GCC ATT TAT AAG
AAT ACG CCG CTT CG) and UPEC-cdiI-XhoI-rev (5=-TTT CTC GAG CCA CCA TCA GGC TGG AC). The product
was digested with NotI/XhoI and ligated to plasmid pCH450 (51). The cdiBAISTECO31 gene cluster (ordered
loci, BE44_RS05220, BE44_RS05225, and BE44_RS0125610) was amplified from E. coli STEC_O31 genomic
DNA using oligonucleotides J2M139-CDI-Not-for (5=-TTT GCG GCC GCA ATG TCT GGT TGT GGC AGG) and
J2M139-CDI-Xho-rev (5=-TTT CTC GAG TGG CCG GAA TCT TTA CTC AG) (http://www.uniprot.org/uniparc/
UPI00026E100C). The product was digested with NotI/XhoI and ligated to plasmids pET21b and pCH450.
The E. coli tsx gene was amplified with tsx-Not-for (5=-TTT GCG GCC GCG AAT TCG GGA TTT TCA AAC AGT
GGC ATA C) and tsx-Xho-rev (5=-TTT CTC GAG TCT AGA AAA TCC CGG CAT TTT CAT AAT CAG) and ligated
TABLE 1 Bacterial strains
Strain Descriptiona
Source or
reference
EPI100 F mcrA Δ(mrr-hsdRMS-mcrBC) 80dlacZM15 lacXcZΔM15
lacX recA1 endA1 araD139 (ara, leu)7697 galU galK 
rpsL nupG Strr
Epicentre
MFDpir MG1655 RP4-2-Tc::[ΔMu1::aac(3)IV-ΔaphA-Δnic35-ΔMu2::zeo]
dapA::(erm-pir) ΔrecA Aprr Zeor Ermr
55
DY378 W3110 cI857 (cro-bioA) 50
DL4259 E. coli MC4100 that expresses GFP-mut3 16
CH2016 X90 (DE3) rna slyD::kan Rifr Kanr 56
CH7175 EPI100 Δwzb Strr 19
CH8119 DH5 pir Biomedal s.l.
(Spain)
CH9597 EPI100 bamA::cat pZS21amp-bamA Strr Cmr Ampr 28
ZR343 EPI100 bamA::cat ΔompC pZS21-bamA Strr Cmr Kanr This study
ZR344 EPI100 bamA::cat ompC pZS21-bamAECL Strr Cmr Kanr This study
ZR345 EPI100 bamA::cat ompCEC536 pZS21-bamA Strr Cmr Kanr This study
ZR346 EPI100 bamA::cat ompCUPEC536 pZS21-bamAECL Strr Cmr Kanr This study
ZR372 EPI100 wzb Δtsx::kan Strr Kanr This study
ZR376 EPI100 wzb tsx Strr This study
ZR412 EPI100 bamA::cat ΔompC::kan pZS21amp-bamA Strr Cmr
Kanr Ampr
This study
ZR413 EPI100 bamA::cat ompC::kan pZS21amp-bamAECL Strr Cmr
Kanr Ampr
This study
aAbbreviations: Ampr, ampicillin resistant; Aprr, apramycin resistant; Cmr, chloramphenicol resistant; Ermr,
erythromycin resistant; Kanr, kanamycin resistant; Rifr, rifampin resistant; Strr, streptomycin resistant; Zeor,
zeocin resistant.
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to plasmid pCH450 using NotI and XhoI restriction sites. The E. coli recA gene was amplified with
recA-BglII (5=-TGC AGA TCT TGT GGC AAC AAT TTC TAC) and recA-Xma (5=-GCG ACC CGG GTG TAT CAA
ACA AGA CG) and ligated to BglII/XmaI-digested plasmid pSIM6 to generate pCH9674.
Plasmid pDAL7912 was constructed by introducing Kan resistance and counterselectable sacB genes
into pDAL660Δ1-39. The sacB and kan genes were amplified from plasmid pRE118 (52) with primers
EC93-1953-sacB-for (5=-CGC CGT TTC TGC CGG T CCC GTA GTC TGC AAA TCC) and EC93-1972-sacB-rev
(5=-GCC ATA GCG ACG ACG TTC TCC GAA AAT GCC AAT AGG ATA TCG GC). Two cdiAEC93 fragments were
then amplified with primer pairs EC93-Chimera-for (5=-ACG TTA AAG GAA CCA CGC TG)/EC93-1953-sacB-
rev (5=-GGA TTT GCA GAC TAC GGG ACC GGC AGA AAC GGC G) and EC93-1972-sacB-for (5=-GCC GAT ATC
CTA TTG GCA TTT TCG GAG AAC GTC GTC GCT ATG GC)/EC93-Chimera-rev (5=-GAA AGT CAC AGC AGA
TGT CGG). The three fragments were combined by overlap-extension PCR (OE-PCR) using primer pair
EC93-chimera-for/EC93-chimera-rev. The resulting product was introduced into plasmid pDAL660Δ1-39
by Red-mediated recombination, and the recombinant pDAL660Δ1-39::sacB-kan plasmid was selected on
Kan-supplemented LB agar.
Chimeric cdiAEC93 genes were constructed by Red-mediated recombination and sucrose counterse-
lection. The receptor-binding region of cdiAEC536 (encoding residues Ala1345 to Trp1668) was amplified
with UPEC1345A (5=-GTC TGT GGG TAC AGA AGG ACG CTT CCG GCG GTG CAA ACA) and UPEC1668W
(5=-TGT TAC CGG ATG GCA GGG GCC AGT CAT CAC TGA TAC CGG). The covarying region of cdiAEC536
(encoding residues Pro1669 to Gly2310) was amplified with UPEC1669P (5=-GGG CAA GTG TAA GCA GCT
ATC CAC TGC CTT CCG GCA ACA A) and UPEC2310G (5=-TCG TGC GTT GTC TTA CTG CTG CCA ATG GTG
AAA CCA ATA CC). The combined receptor-binding and covarying regions were amplified with primer
pair UPEC1345A/UPEC2310G. Homology regions from cdiAEC93 were amplified with EC93-Chimera-for/
UPEC1345-rev (5=-TGT TTG CAC CGC CGG AAG CGT CCT TCT GTA CCC ACA GAC) encoding Asp1124 to
Asp1346, EC93-Chimera-for/UPEC1669-rev (5=-TTG TTG CCG GAA GGC AGT GGA TAG CTG CTT ACA CTT
GCC C) encoding Asp1124 to Tyr1636, UPEC1668-for (5=-CCG GTA TCA GTG ATG ACT GGC CCC TGC CAT
CCG GTA ACA)/EC93-Chimera-rev encoding Pro1637 to Gly2508, and UPEC2311-for (5=-GGT ATT GGT TTC
ACC ATT GGC AGC AGT AAG ACA ACG CAC GA)/EC93-Chimera-rev encoding Ser2207 to Gly2508. The
resulting fragments were joined to cdiAEC536 amplicons using OE-PCR with primer pair EC93-Chimera-
for/EC93-Chimera-rev. The final products were introduced into plasmid pDAL7912 by Red-mediated
TABLE 2 Plasmids
Plasmid Descriptiona
Source or
reference
pWEB-TNC Cosmid cloning vector; Ampr Cmr Epicentre
pCP20 Heat-inducible expression of FLP recombinase; Cmr Ampr 57
pSC189 Mobilizable plasmid with R6K replication origin; carries the mariner transposon containing
kanamycin resistance cassette; Ampr Kanr
58
pRE118 Vector plasmid for allelic exchange; Kanr 52
pSIM5 Heat-inducible expression of the phage  Red recombinase proteins; Cmr 59
pSIM6 Heat-inducible expression of the phage  Red recombinase proteins; Ampr 59
pDsRedExpress2 Constitutive expression of DsRed; Ampr Clontech
pZS21-bamA pZS21 derivative that expresses bamAEco; Kanr 60
pZS21-bamAECL Expresses bamAECL from Enterobacter cloacae ATCC 13047; Kanr 28
pZS21amp-bamA pZS21amp derivative that expresses E. coli bamA; Ampr 24
pZS21amp-bamAECL pZS21amp derivative that expresses E. cloacae bamA; Ampr 28
pDAL660Δ1-39 Constitutively expresses the cdiBAIEC93 gene cluster; Ampr Cmr 3
pDAL7718 pDAL660Δ1-39 derivative that expresses chimeric CdiAEC93 with residues Ser1347 to Tyr1636
replaced with Ala1345 to Trp1668 from CdiAEC536; Ampr Cmr
This study
pDAL7720 pDAL660Δ1-39 derivative that expresses chimeric CdiAEC93 with residues Ser1347 to Gly2205
replaced with residues Ala1345 to Gly2310 from CdiAEC536; Ampr Cmr
This study
pDAL7912 pDAL660Δ1-39::kan-sacB; Ampr Cmr Kanr This study
pDAL7936 pDAL660Δ1-39 derivative that expresses chimeric CdiAEC93 with residues Pro1637 to Gly2205
replaced with residues Pro1669 to Gly2310 from CdiAEC536; Ampr Cmr
This study
pCH450 pACYC184 derivative with E. coli araBAD promoter for arabinose-inducible expression; Tetr 51
pCH7277 pSH21::arfA, contains a SpeI site to generate in-frame N-terminal His6 fusion proteins; Ampr 61
pCH8619 pSH21::cdiA(Q2681–A2909); Ampr This study
pCH9216 pSH21::(ss)bamAEco; overproduces E. coli BamA lacking the signal sequence peptide; Ampr This study
pCH9231 pSH21::(ss)bamAECL; overproduces E. cloacae BamA lacking the signal sequence peptide; Ampr This study
pCH9674 pSIM6 derivative in which the phage  red genes have been replaced with E. coli recA; Ampr This study
pCH9718 pSH21::cdiA(R1358–R1646); Ampr This study
pCH10235 pSH21::cdiA(R1358–R2123); Ampr This study
pCH10316 pSH21::cdiA(N2556–V2727); Ampr This study
pCH10319 pSH21::cdiA(G1953–N2556); Ampr This study
pCH12352 pCH450::cdiBAIEC536; Tetr This study
pCH13602 pCH450::cdiBAISTECO31; Tetr This study
pCH13603 pCH450::tsx; Tetr This study
pCH13604 pET21b::cdiBAISTECO31; Ampr This study
aAbbreviations: Ampr, ampicillin resistant; Spcr, spectinomycin resistant; Kanr, kanamycin resistant; Tmpr, trimethoprim resistant; Tetr, tetracycline resistant.
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recombination, and chimeric recombinants were selected on no-salt LB agar supplemented with Amp
and 5% sucrose. The identities of all plasmid constructs were confirmed by DNA sequence analysis.
Protein purification. BamAEco and BamAECL were overproduced in E. coli CH2016 grown at 37°C in
LB medium supplemented with Amp and 1.5 mM IPTG (isopropyl--D-thiogalactopyranoside). Though
the plasmid constructs encode N-terminal His6 epitopes, we found that these tags were removed,
precluding the use of Ni2 affinity chromatography. Therefore, we isolated BamA proteins from insoluble
inclusion bodies. Bacteria were harvested by centrifugation, and the cell pellets were suspended in 5 ml
of BugBuster reagent and incubated on a rotisserie at room temperature for 20 min. Next, cells were
harvested by centrifugation at 6,000  g for 10 min, and the supernatant was decanted to remove
soluble proteins. Cells were then resuspended in 5 ml of BugBuster reagent and broken by three
passages through a French press. Lysates were diluted with 25 ml deionized water and vortexed
vigorously. Inclusion bodies were collected by centrifugation at 15,000  g for 20 min and washed three
times with 5 ml of 0.1 BugBuster solution. Isolated inclusion bodies were dissolved in 0.5 ml of urea
lysis buffer (8 M urea, 10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 20 mM imidazole, 0.05% Triton X-100).
Residual His6-tagged BamA was removed by overnight incubation with urea lysis buffer-equilibrated
Ni2-nitrilotriacetic acid (NTA) agarose resin. Unbound protein was collected by centrifugation through
an 0.45-m nylon Costar Spin-X column and diluted into 10 mM Tris-HCl (pH 8.0)-0.5% Triton X-100.
Refolding reaction mixtures were incubated on a rotisserie for 3 days at ambient temperature, followed
by 3 weeks at 4°C. More than 95% of BamA was refolded as determined by heat-modifiable gel mobility
as previously described (53).
His6-tagged CdiAEC93 fragments were overproduced in E. coli CH2016 grown at 37°C in LB medium
supplemented with Amp and 1.5 mM IPTG. Bacteria were harvested by centrifugation, and the cell pellets
were frozen at 80°C and then resuspended directly in 15 ml urea lysis buffer. Cells were disrupted by
two freeze-thaw cycles. Insoluble debris was removed through two rounds of centrifugation at 15,000 
g for 20 min. Ni2-NTA agarose resin was equilibrated in urea lysis buffer and added to each clarified
lysate, and the mixtures were incubated on a rotisserie for 90 min at ambient temperature. The resin was
collected by centrifugation at 3,000  g for 30 s, resuspended in 5 ml urea lysis buffer, and transferred
to a fresh tube. After three washes with 5 ml urea lysis buffer, resin-bound His6-CdiAEC93 fragments were
refolded with three washes of 5 ml native lysis buffer (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 30 mM
imidazole, 0.05% Triton X-100). After the final wash, resins were resuspended in 250 l of binding buffer
(10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 30 mM imidazole, 0.5% Triton X-100) for use in BamA-binding
experiments.
BamA-binding assays. Refolded BamAEco and BamAECL were diluted to 10 M in 1 ml of binding
buffer. Ni2-NTA agarose resin (20 l) containing bound His6-CdiAEC93 fragments was added to the BamA
solutions, and the mixtures were incubated on a rotisserie for 90 min at 4°C. Resins were collected by
centrifugation at 3,000  g for 30 s, resuspended in 1 ml of binding buffer, and transferred to a fresh
tube. The resins were washed three times with binding buffer and then eluted with binding buffer
supplemented with 25 mM EDTA. Eluted proteins were run on SDS-10% polyacrylamide gels and blotted
onto nitrocellulose for immunoblot analysis using polyclonal antibodies raised against BamAEco. Blots
were visualized using IRDye 680 (Li-Cor)-labeled anti-rabbit secondary antibodies and an Odyssey
infrared imager as described previously (54).
Cell-cell adhesion assays. BamAEco-binding studies were conducted using E. coli strain DL4259,
which expresses gfp-mut3 from the papBA promoter (19). E. coli DL4259 cells were transformed with
pDAL660Δ1-39 (CdiAEC93), pCH12352 (CdiAEC536), pDAL7718 (CdiAEC93-RBREC536), pDAL7936 (CdiAEC93-
CVREC536), pDAL7720 (CdiAEC93-RBR/CVREC536), or pCH13604 (CDISTECO31), and the resulting strains were
grown at 37°C in LB medium (supplemented with Amp or Tet) until the cells developed fluorescence. The
expression of each CdiA effector was assessed by immunoblot analysis of total urea-soluble protein using
polyclonal antibodies raised against the N-terminal TPS transport domain of CdiAEC93 (38). Target cells
were fluorescently labeled with DsRed using plasmid pDsRedExpress2. For Tsx-dependent adhesion
experiments, the target cells were grown overnight in LB supplemented with Tet, Amp, 0.4% arabinose,
and 1 mM IPTG to induce expression of Tsx and DsRed prior to mixing with inhibitors. GFP-labeled
inhibitor cells were mixed at a 5:1 ratio with DsRed-labeled target bacteria at a final OD600 of 0.2. Cell
suspensions were shaken at 30°C for 20 min, diluted into 1 PBS, vortexed briefly, and then analyzed on
an Accuri C6 flow cytometer using FL1 (533/30 nm, GFP) and FL2 (585/40 nm, DsRed) fluorophore filters.
The fraction of target bacteria bound to inhibitor cells was calculated as the number of dual green/red
fluorescent events divided by the total number of red fluorescent events.
Transposon library construction and selection for CDIr mutants. The mariner transposon was
introduced into E. coli CH7175 cells through conjugation with E. coli MFDpir donor cells carrying plasmid
pSC189. Donor cells were grown to mid-log phase in LB medium supplemented with Amp and 30 M
diaminopimelic acid. Donors and recipients were mixed and incubated on LB agar for 4 h at 37°C. Cell
mixtures were harvested with a sterile swab, diluted into 1 M9 medium, and plated onto Kan-
supplemented LB agar to select transposon mutants. The following day, the mutant pool (~100,000 Kanr
colonies) was harvested into 1 ml of 1 M9 medium. Mutant pools were cocultured with E. coli EPI100
cells carrying plasmid pCH13604 in LB medium overnight at 37°C, and target bacteria were selected on
Kan-supplemented LB agar. The surviving target cell colonies were harvested into 1 M9 medium and
subjected to two additional cycles of coculture selection. Four CDIr clones were randomly selected from
each of the three independently prepared transposon mutant pools. Transposon insertion sites were
identified by rescue cloning. Chromosomal DNA from each CDIr mutant was digested with NspI
overnight at 37°C. The restriction endonuclease was inactivated at 65°C for 20 min, and reaction mixtures
were supplemented with ATP and T4 DNA ligase for overnight incubation at 16°C. The ligated DNA was
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electroporated into E. coli DH5 pir cells. Plasmids were isolated from resulting Kan-resistant transfor-
mants, and transposon insertion junctions were identified by DNA sequencing using primer mariner-
rev-seq (5=-CAA GCT TGT CAT CGT CAT CC).
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